Curative Biotechnology Taps Golden Eagle Capital for Global Expansion

Curative Biotechnology, Inc. (OTC: CUBT), a development-stage biomedical company focused on novel therapies for rare diseases, has engaged Golden Eagle Capital Advisors, Inc. (GECA) as its exclusive agent and strategic advisor. This strategic partnership aims to facilitate CUBT's global expansion and access to capital, as the company focuses on its degenerative eye disease platform.

GECA's international presence and network, spanning Dubai, New York, Hong Kong, Milan, and London, provide CUBT with a global platform for expansion and investment opportunities. This extensive network enables CUBT to tap into diverse markets, access capital, and identify strategic partnerships. GECA's expertise in investment banking and wealth management further enhances CUBT's ability to navigate international financial landscapes, potentially accelerating its growth and success in the global biomedical market.

GECA's comprehensive suite of bespoke investment and financial advisory solutions, complemented by a personalized red-carpet banking experience, will help CUBT secure funding for its innovative therapies. By leveraging GECA's global network and dynamic professionals, CUBT can build a strong investor base, fostering growth and success in its mission to develop novel treatments for rare diseases.



CUBT's degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH), is a key focus for the company. The first therapeutic in development on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). With GECA's support, CUBT aims to be in the clinic in 2025 for a first-in-human trial of the metformin-based eye drop under a Cooperative Research and Development Agreement (CRADA) with the NEI.

In conclusion, Curative Biotechnology's partnership with Golden Eagle Capital Advisors is a strategic move that positions the company for global expansion and success. By leveraging GECA's international network and financial expertise, CUBT can accelerate its drug development programs and bring innovative therapies to market, ultimately improving the lives of patients with rare diseases.